Guest Editors
Dr. Jeanny B. Aragon-Ching
Email: jeanny.aragon-ching@inova.org
Affiliation: Inova Schar Cancer Institute, Inova Health System,8081 Innovation Park Drive, Fairfax, VA 22031, USA
Homepage:
Research Interests: Bladder Cancer, Kidney Cancer, Prostate Cancer
Dr. Ravi Madan
Email: madanr@mail.nih.gov
Affiliation: National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
Homepage:
Research Interests: PSMA PET, biochemical recurrence, therapeutics
Summary
Prostate cancer is the most common solid tumor in men and a leading cause of cancer-related mortality, especially in its advanced stages. While localized prostate cancer is typically curable, recurrent or metastatic forms, particularly castration-resistant prostate cancer (CRPC), remain significant therapeutic challenges. In recent years, biomarkers such as prostate-specific membrane antigen (PSMA) have shown considerable promise in precision diagnosis and biochemical recurrence (BCR) detection. In terms of treatment, advances in androgen receptor pathway inhibitors (ARPIs), chemotherapy, radioligand therapies (such as Lu-177 and Ra-223), and PARP inhibitors continue to expand the therapeutic options available. This special issue aims to explore the latest research in diagnostic tools, therapeutic strategies, and resistance mechanisms to advance the ongoing management of prostate cancer.
Scope and Themes
Including but not limited to the following topics:
- PSMA-PET imaging and its application in biochemical recurrence
- Emerging diagnostic and prognostic biomarkers
- Androgen receptor pathways and resistance mechanisms in castration-resistant prostate cancer
- Radioligand therapy and new radiopharmaceuticals
- PARP inhibitors and DNA repair pathway-targeted therapies
- Sequencing and combination strategies in chemotherapy
- Immunotherapy and tumor vaccine exploration
- Precision medicine and molecular characterization
- Advanced imaging techniques in treatment monitoring
This special issue seeks to compile research findings across multiple dimensions of prostate cancer diagnosis, prognosis, and treatment, emphasizing the connection between basic science and clinical translation, and highlighting the role of precision medicine in shaping future therapeutic strategies.
Keywords
biochemical recurrence, biomarkers, PSMA, PSADT, MRI, metastatic castration sensitive prostate cancer, metastatic castration-resistant prostate cancer, chemotherapy, radioligand therapy, androgen deprivation therapy, androgen receptor pathway inhibitors, poly-ADP ribose polymerase inhibitors, radium, lutetium
Login
Register
Submit a Paper
Propose a Special lssue